Float Short %

23.38

Margin Of Safety %

Put/Call OI Ratio

0.37

EPS Next Q Diff

-0.37

EPS Last/This Y

-3.21

EPS This/Next Y

0.14

Price

40.52

Target Price

80.65

Analyst Recom

2.1

Performance Q

-17.29

Relative Volume

0.77

Beta

1.66

Ticker: CRSP

20 items of 1

Date	Symbol	Last	P/C OI	P/C Vol	Total OI
2024-12-19	CRSP	40.38	0.50	0.49	92503
2024-12-20	CRSP	40.7	0.46	0.86	92546
2024-12-23	CRSP	40.5	0.50	0.94	81184
2024-12-24	CRSP	40.84	0.48	0.38	83741
2024-12-26	CRSP	41.08	0.48	1.24	84608
2024-12-27	CRSP	39.96	0.47	0.21	86107
2024-12-30	CRSP	38.69	0.48	0.60	82727
2024-12-31	CRSP	39.38	0.48	0.26	86644
2025-01-02	CRSP	41.42	0.48	0.14	89299
2025-01-03	CRSP	41.02	0.46	0.33	92955
2025-01-06	CRSP	42.45	0.47	0.39	90382
2025-01-07	CRSP	41.93	0.45	0.71	91363
2025-01-08	CRSP	41.27	0.46	1.07	92938
2025-01-09	CRSP	41.29	0.46	1.01	92938
2025-01-10	CRSP	39.67	0.45	0.47	93000
2025-01-13	CRSP	38.88	0.45	0.58	91166
2025-01-14	CRSP	38.35	0.43	0.24	93235
2025-01-15	CRSP	39.36	0.41	0.49	93032
2025-01-16	CRSP	40.26	0.40	0.77	93250
2025-01-17	CRSP	40.52	0.37	1.05	92075
Date	Symbol	Last	P/C OI	P/C Vol	Total OI

20 items 1 of 1

20 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2024-12-19	CRSP	40.39	-209.6	-48.3	-5.15
2024-12-20	CRSP	40.71	-209.6	-67.3	-5.15
2024-12-23	CRSP	40.48	-209.6	-56.3	-5.15
2024-12-24	CRSP	40.94	-209.6	-69.8	-5.15
2024-12-26	CRSP	41.07	-209.6	-63.4	-5.15
2024-12-27	CRSP	40.03	-209.6	-41.5	-5.15
2024-12-30	CRSP	38.65	-209.6	-33.9	-5.15
2024-12-31	CRSP	39.37	-209.6	-76.0	-5.15
2025-01-02	CRSP	41.40	-209.6	-102.3	-5.15
2025-01-03	CRSP	41.03	-209.6	-53.6	-5.15
2025-01-06	CRSP	42.43	-209.6	-87.3	-5.15
2025-01-07	CRSP	41.94	-209.6	-52.3	-5.15
2025-01-08	CRSP	41.29	-209.6	-49.7	-5.15
2025-01-09	CRSP	41.29	-209.6	-60.9	-5.15
2025-01-10	CRSP	39.65	-209.6	-30.6	-5.15
2025-01-13	CRSP	38.85	-209.6	-44.0	-5.15
2025-01-14	CRSP	38.36	-209.6	-50.5	-5.15
2025-01-15	CRSP	39.07	-209.6	-76.2	-5.15
2025-01-16	CRSP	40.28	-209.6	-86.6	-5.15
2025-01-17	CRSP	40.52	-209.6	-65.1	-5.15
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

20 items 1 of 1

20 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2024-12-19	CRSP	-1.45	10.00	22.22
2024-12-20	CRSP	-1.45	10.00	22.22
2024-12-23	CRSP	-1.44	9.89	22.22
2024-12-24	CRSP	-1.44	9.89	22.22
2024-12-26	CRSP	-1.35	9.89	22.17
2024-12-27	CRSP	-1.36	9.89	22.17
2024-12-30	CRSP	-1.40	9.90	22.17
2024-12-31	CRSP	-1.40	9.90	22.17
2025-01-02	CRSP	-1.34	9.90	22.18
2025-01-03	CRSP	-1.35	9.90	22.18
2025-01-06	CRSP	-1.37	9.90	22.18
2025-01-07	CRSP	-1.37	9.90	22.18
2025-01-08	CRSP	-1.35	9.90	22.18
2025-01-09	CRSP	-1.35	9.90	22.18
2025-01-10	CRSP	-1.35	9.90	22.18
2025-01-13	CRSP	-1.35	9.91	23.38
2025-01-14	CRSP	-1.35	9.91	23.38
2025-01-15	CRSP	-1.35	9.91	23.38
2025-01-16	CRSP	-1.35	9.91	23.38
2025-01-17	CRSP	-1.35	9.91	23.38
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

20 items 1 of 1

Last Quarter Act. EPS

-1.01

Avg. EPS Est. Current Quarter

-1.21

Avg. EPS Est. Next Quarter

-1.38

Insider Transactions

-1.35

Institutional Transactions

9.91

Beta

1.66

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

81.6

Max Drawdown 5-Year %

-81.7

Target Price

80.65

P/E

Forward P/E

PEG

P/S

17.06

P/B

1.78

P/Free Cash Flow

EPS

-2.82

Average EPS Est. Cur. Y

-5.15

EPS Next Y. (Est.)

-5.01

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-118.13

Relative Volume

0.77

Return on Equity vs Sector %

-31.4

Return on Equity vs Industry %

-18.8

EPS 1 7Days Diff

EPS 1 30Days Diff

-0.01

EBIT Estimation

-65.1

CRISPR Therapeutics AG

Sector: Healthcare

Industry: Biotechnology

Employees: 407

CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA. The company has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, immune-oncology and autoimmune, in vivo, and type 1 diabetes. The company's lead product candidate is CASGEVY, an ex vivo CRISPR/Cas9 gene-edited cell therapy for treating patients suffering from transfusion-dependent beta-thalassemia, severe sickle cell disease, and hemoglobinopathies in which a patient's hematopoietic stem and progenitor cells are edited to produce high levels of fetal hemoglobin in red blood cells. It also develops CAR T cell therapies, including CTX112 targeting CD19 and CTX131 targeting CD70 for oncology and autoimmunune indications; CTX310 and CTX320, in vivo gene editing to address the cardiovascular disease by disrupting the validated targets angiopoietin-like protein 3 and lipoprotein; and VCTX211, an allogeneic, gene-edited, hypoimmune stem cell-derived product candidate for the treatment of T1D. It has strategic partnerships with Vertex Pharmaceuticals Incorporated, ViaCyte, Inc., Nkarta, Inc., and Capsida Biotherapeutics. CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland.

stock quote shares CRSP – CRISPR Therapeutics AG Stock Price stock today

news today CRSP – CRISPR Therapeutics AG stock forecast ,stock prediction 2023 2024 2025

marketwatch CRSP – CRISPR Therapeutics AG yahoo finance google finance

stock history CRSP – CRISPR Therapeutics AG invest stock market

stock prices CRSP premarket after hours

ticker CRSP fair value insiders trading

Investment involves risk. As a general rule, you should only trade in financial products that you are familiar with and understand the risk associated with them. The risk warning described in each financial product below is not exhaustive, you should carefully consider your investment experience, financial situation, investment objective, risk tolerance level and consult your independent financial adviser as to the suitability of your situation prior making any investment.

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Relative Volume

Beta

Ticker: CRSP

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Get Started

About

Last Quarter Act. EPS

Average EPS Est. Cur. Y